Navigation Links
As Pharmaceutical Deal Making Becomes More Competitive, PharmaDeals(R) Resource Expands its Deal Coverage
Date:8/19/2010

As Pharmaceutical Deal Making Becomes More Competitive, PharmaDeals(R) Resource Expands its Deal... -- OXFORD, England, August 19, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Cosmetics and Personal Care, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, New Products & Services Click to view news release full screen  

As Pharmaceutical Deal Making Becomes More Competitive, PharmaDeals(R) Resource Expands its Deal Coverage

 

OXFORD, England, August 19, 2010 /PRNewswire/ -- PharmaVentures, the company behind the PharmaDeals(R) range of business information, announced today the expansion of its PharmaDeals Agreements coverage that includes exclusive interviews with deal makers around the world. The announcement follows major enhancement of its dedicated, market leading platform delivering deal data and information to the pharmaceutical and biotechnology sector.

The scope of PharmaDeals Agreements database has been expanded to include categories of deals that have medical and therapeutic applications in cosmetics, internet and e-commerce, nutritional supplements, packaging, wound care, bioterrorism, as well as deeper classifications within drug delivery technologies.

Fintan Walton, PhD, Chief Executive of PharmaVentures, says, "We are very excited about our latest version of PharmaDeals. One of the big issues that face those in researching and analysing deals is the lack of scope within databases they use which is a result of the huge changes taking place in the world of deal making. More companies are doing specialist deals, for example, with orphan drugs, and the world is changing as new technologies, mechanisms of action and even new therapy areas emerge. Frankly no one else has tried to come up with solutions to these changes."

New content is also being sourced related to deal making by Clinical Research and Contract Manufacturing Organizations. The development to the database augments recent improvements to the classifications and user interface.

As deal making is a people business subscribers can for the first time access exclusive television interviews with the key deal makers in the major pharmaceutical companies as well as key influencers at the corporate level such as CEOs and Board Members of corporations.

Dr Walton continues, "A key priority for us is to better serve our customers with information about deals from rapidly developing markets, and we have done this by considerably increasing our sources, especially in India, China, and generally within South Asia and South America. These developments to our content are additional key milestones for us, and, in the very near future, we shall be bringing news of further offerings to help our clients' ability to win the best deals for them."

Notes to Editors:

About PharmaVentures

PharmaVentures Limited (http://www.pharmaventures.com) is based in Oxford, England and is a leading international corporate advisory firm supporting its clients' growth ambitions through licensing, joint ventures and M&A in the healthcare industry. The company works for a variety of clients from start-ups to global pharmaceutical corporations, their advisors, investment companies and government bodies. It also produces the highly popular PharmaDeals(R) range of intelligence products including analysis tools and reports. In 2006, it launched the world's first dedicated online pharmaceutical television channel PharmaTelevision(R) ( http://www.pharmatelevision.com)

http://www.pharmaventures.com http://www.pharmadeals.net http://www.pharmatelevision.com PharmaDeals(R) is a registered Trade Mark of PharmaVentures Ltd.

For further information about PharmaDeals and other PharmaVentures products and services, including ordering, please contact:

Doug Cookson Commercial Director, PharmaVentures Magdalen Centre Oxford Science Park Oxfordshire OX4 4GA, UK T: +44(0)1865-332731 E: doug.cookson@pharmaventures.com
'/>"/>

SOURCE PharmaVentures
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Protectus Medical Devices Appoints as Medical Director a Physician Surgeon With 20-Year Involvement in Senior Level Monitoring of Pharmaceutical and Medical Devices
2. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
3. Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human
4. RedOak Logics Mission: Transform Pharmaceutical Industry Drug Development
5. Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million
6. Decision Resources Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
7. Trubion Pharmaceuticals Inc. Reports Second-Quarter and First-Half 2010 Financial Results
8. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
9. Ferring Pharmaceuticals FIRMAGON® Joins Race to End Prostate Cancer as Official Sponsor of the Great Prostate Cancer Challenge / Dash for Dad
10. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
11. Reportlinker Adds Effective Social Media Marketing Strategies for Pharmaceutical Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... CITY, Calif. , Feb. 4, 2016 /PRNewswire/ ... "Company") today announced it has entered into a ... Exchange Commission (SEC) fully resolving the SEC,s investigation ... Act (FCPA).  Under the terms of the settlement ... of $12.8 million, including disgorgement, pre-judgment interest and ...
(Date:2/4/2016)... Global Immunology Market to 2022 - ... market growth Summary Immune-mediated inflammatory diseases ... that affect 5–7% of western populations. Although they ... and key patient demographics, they are pathophysiologically linked, ... an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, ...
(Date:2/4/2016)... 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... devices to treat life-threatening diseases, today announced results ... December 31, 2015. --> ... forth in our last quarterly call, we strategically ... long-term objective to establish the Aethlon Hemopurifier® as ...
Breaking Medicine Technology:
(Date:2/6/2016)... CA (PRWEB) , ... February 06, 2016 , ... US ... Ultimate Coaching Conference (YUCC) . This event brings together top non-profit leaders, ultimate organizations, ... Equity and Girls Ultimate”. Valerio Iani, Bay Area Disc Program Director of Youth and ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research has ... helps to reduce the frequency and level of relapse. , At ... Identity and Purpose,” will explore the critical tasks of the recovery phase and ...
(Date:2/5/2016)... Ontario (PRWEB) , ... February 05, 2016 , ... ... announced the availability of the company's lighter, sleeker next generation LYNX VR Indoor ... plant. , Improvements in design and manufacturing not only reduce the weight ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being ... Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for ... of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative ...
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute Valentine’s ... the tips of your toes. Foot massage, whether administered by a professional masseuse or ... relaxation. The American Board of Multiple Specialties in Podiatry (ABMSP) has taken ...
Breaking Medicine News(10 mins):